BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15870726)

  • 1. An Achilles' heel for breast cancer?
    Caldecott KW; Chalmers A
    Nat Struct Mol Biol; 2005 May; 12(5):387-8. PubMed ID: 15870726
    [No Abstract]   [Full Text] [Related]  

  • 2. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
    Stebbing J; Ellis P; Tutt A
    Future Oncol; 2010 Apr; 6(4):485-6. PubMed ID: 20373860
    [No Abstract]   [Full Text] [Related]  

  • 3. PARP inhibitors: will the new class of drugs match the hype?
    Tuma RS
    J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
    [No Abstract]   [Full Text] [Related]  

  • 4. PARP inhibitors: targeting the right patients.
    Azvolinsky A
    J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of PARP inhibitors: an unfinished story.
    Patel A; Kaufmann SH
    Oncology (Williston Park); 2010 Jan; 24(1):66, 68. PubMed ID: 20187324
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer: crossing over to drug resistance.
    Livingston DM; Silver DP
    Nature; 2008 Feb; 451(7182):1066-7. PubMed ID: 18305536
    [No Abstract]   [Full Text] [Related]  

  • 7. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
    Carden CP; Yap TA; Kaye SB
    Curr Opin Oncol; 2010 Sep; 22(5):473-80. PubMed ID: 20485165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel targets for triple-negative breast cancer.
    Carey LA
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
    [No Abstract]   [Full Text] [Related]  

  • 9. PARP inhibition in breast cancer.
    Garber J
    Clin Adv Hematol Oncol; 2009 Sep; 7(9):573-5. PubMed ID: 20020667
    [No Abstract]   [Full Text] [Related]  

  • 10. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
    Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
    J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
    Bouwman P; Jonkers J
    Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
    Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
    Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PARP inhibitors and breast cancer: update and perspectives].
    Gonçalves A
    Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibition as a prototype for synthetic lethal screens.
    Liu X
    Methods Mol Biol; 2013; 986():123-37. PubMed ID: 23436410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.
    Hay T; Jenkins H; Sansom OJ; Martin NM; Smith GC; Clarke AR
    Cancer Res; 2005 Nov; 65(22):10145-8. PubMed ID: 16287996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.